News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
US FDA Warns Eli Lilly and Company, Sanofi-Aventis (France), Meda AB on Misleading Promotions
February 4, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- U.S. health officials have warned Sanofi Aventis SA, Eli Lilly & Co and Meda AB about misleading promotions for prescription drugs, letters released on Wednesday said.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Regulatory
Eli Lilly and Company
Food and Drug Administration (FDA)
Sanofi (France)
MORE ON THIS TOPIC
Approvals
Sentynl, Fortress Bounce Back With FDA Approval for Rare Pediatric Disease
January 13, 2026
·
2 min read
·
Tristan Manalac
Regulatory
FDA Carves Out Manufacturing Exemptions for CGTs To Accelerate Development
January 12, 2026
·
2 min read
·
Tristan Manalac
Policy
Flagship CEO Calls Out Attacks on Science, Warns of China Dominance
January 12, 2026
·
4 min read
·
Heather McKenzie
FDA
6 FDA Decisions To Watch in Q1 2026
January 12, 2026
·
8 min read
·
Tristan Manalac